Interleukin-18 for predicting the development of macrophage activation syndrome in systemic juvenile idiopathic arthritis

被引:128
|
作者
Shimizu, Masaki [1 ]
Nakagishi, Yasuo [2 ]
Inoue, Natsumi [1 ]
Mizuta, Mao [2 ]
Ko, Giyo [3 ]
Saikawa, Yutaka [3 ]
Kubota, Tomohiro [4 ]
Yamasaki, Yuichi [4 ]
Takei, Syuji [4 ]
Yachie, Akihiro [1 ]
机构
[1] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Sch Med, Dept Pediat, Kanazawa, Ishikawa 9208641, Japan
[2] Hyogo Prefectural Kobe Childrens Hosp, Dept Pediat Rheumatol, Kobe, Hyogo, Japan
[3] Kanazawa Med Univ, Sch Med, Dept Pediat, Uchinada, Ishikawa 92002, Japan
[4] Kagoshima Univ, Fac Med, Sch Med, Dept Pediat, Kagoshima 890, Japan
关键词
Interleukin-18 (IL-18); Prediction of macrophage activation syndrome; Systemic juvenile idiopathic arthritis; KILLER-CELL DYSFUNCTION; ADULT-ONSET; RHEUMATOID-ARTHRITIS; DIAGNOSTIC-SIGNIFICANCE; GAMMA PRODUCTION; DISEASE; PATHOPHYSIOLOGY; TOCILIZUMAB; CYTOKINE; PATHOGENESIS;
D O I
10.1016/j.clim.2015.06.005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
To assess the role of IL-6/IL-18 in the pathogenesis of systemic juvenile idiopathic arthritis (s-JIA) and to investigate the clinical significance of serum IL-18 levels for predicting macrophage activation syndrome (MAS) development, we measured the serum IL-6/IL-18 levels in 76 s-JIA patients, including 15 with MAS, and compared them with the clinical features. We identified 2 distinct subsets on the basis of serum IL-6/IL-18 levels. The IL-18-dominant subset had more patients who developed MAS. Serum IL-18 levels during active phase in patients with MAS were significantly higher than those without MAS. The cutoff value of serum IL-18 levels for predicting MAS development was 47750 pg/ml. The patients with IL-18 dominant subset at their disease onset were significantly more likely to develop MAS after TCZ therapy started. IL-18 might have a key role in the pathogenesis of MAS. Serum IL-18 levels >47750 pg/ml might be useful to predict MAS development. (C) 2015 Elsevier Inc. All rights reserved.
引用
收藏
页码:277 / 281
页数:5
相关论文
共 50 条
  • [1] Interleukin-18 as a mediator of systemic juvenile idiopathic arthritis
    Marija Jelušić
    Ivan Krešimir Lukić
    Lana Tambić-Bukovac
    Klara Dubravčić
    Ivan Malčić
    Igor Rudan
    Drago Batinić
    [J]. Clinical Rheumatology, 2007, 26 : 1332 - 1334
  • [2] Interleukin-18 as a mediator of systemic juvenile idiopathic arthritis
    Jelusic, Marija
    Lukic, Ivan Kresimir
    Tambic-Bukovac, Lana
    Dubravcic, Klara
    Malcic, Ivan
    Rudan, Igor
    Batinic, Drago
    [J]. CLINICAL RHEUMATOLOGY, 2007, 26 (08) : 1332 - 1334
  • [3] Increased interleukin-18 expression in bone marrow of a patient with systemic juvenile idiopathic arthritis and unrecognized macrophage-activation syndrome
    Maeno, N
    Takei, S
    Imanaka, H
    Yamamoto, K
    Kuriwaki, K
    Kawano, Y
    Oda, H
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (06): : 1935 - 1938
  • [4] Cytokines in Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome: Tipping the Balance Between Interleukin-18 and Interferon-Gamma
    Put, Karen
    Avau, Anneleen
    Brisse, Ellen
    Mitera, Tania
    Put, Stephanie
    Proost, Paul
    Bader-Meunier, Brigitte
    Westhovens, Rene
    Van den Eynde, Benoit
    Orabona, Ciriana
    Fallarino, Francesca
    De Somer, Lien
    Tousseyn, Thomas
    Quartier, Pierre
    Wouters, Carine
    Matthys, Patrick
    [J]. ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S135 - S135
  • [5] Interleukin-18 as a mediator of systemic juvenile idiopathic arthritis (JIA)
    Jeusic, M
    Bukovac, LT
    Malcic, I
    Lukic, IK
    Dubravcic, K
    Batinic, D
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 142 - 142
  • [6] Macrophage activation syndrome in systemic juvenile idiopathic arthritis
    Shimizu, Masaki
    [J]. IMMUNOLOGICAL MEDICINE, 2021, 44 (04) : 237 - 245
  • [7] Interleukin-18 promoter polymorphisms in systemic juvenile idiopathic arthritis.
    D'Urbano, LE
    Muratori, F
    Cortis, E
    Insalaco, A
    de Benedetti, F
    Ugazio, AG
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S364 - S365
  • [8] Tocilizumab masks the clinical symptoms of systemic juvenile idiopathic arthritis-associated macrophage activation syndrome: The diagnostic significance of interleukin-18 and interleukin-6
    Shimizu, Masaki
    Nakagishi, Yasuo
    Kasai, Kazuko
    Yamasaki, Yuichi
    Miyoshi, Mari
    Takei, Syuji
    Yachie, Akihiro
    [J]. CYTOKINE, 2012, 58 (02) : 287 - 294
  • [9] Systemic Juvenile Idiopathic Arthritis Complicated by Macrophage Activation Syndrome
    Wagner-Weiner, Linda
    [J]. PEDIATRIC ANNALS, 2015, 44 (06): : E142 - E147
  • [10] Macrophage activation syndrome and systemic onset of juvenile idiopathic arthritis
    Iglesias Jimenez, E.
    Camacho Lovillo, M. S.
    Lirola Cruz, M. J.
    Falcon Neyra, D.
    Neth, O.
    [J]. ANALES DE PEDIATRIA, 2010, 72 (03): : 230 - 231